- MYGN has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $81.0 million.
- MYGN has traded 451,922 shares today.
- MYGN is down 3.3% today.
- MYGN was up 15.1% yesterday.
EXCLUSIVE OFFER: Get the inside scoop on opportunities in MYGN with the Ticky from Trade-Ideas. See the FREE profile for MYGN NOW at Trade-Ideas More details on MYGN: Myriad Genetics, Inc., a molecular diagnostic company, focuses on the development and marketing of predictive medicine, personalized medicine, and prognostic medicine tests primarily in the United States. MYGN has a PE ratio of 11.7. Currently there are 4 analysts that rate Myriad Genetics a buy, 2 analysts rate it a sell, and 9 rate it a hold. The average volume for Myriad Genetics has been 2.3 million shares per day over the past 30 days. Myriad has a market cap of $2.0 billion and is part of the services sector and diversified services industry. The stock has a beta of 0.69 and a short float of 54.5% with 14.14 days to cover. Shares are up 49.1% year-to-date as of the close of trading on Wednesday. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more. TheStreetRatings.com Analysis: TheStreet Quant Ratings rates Myriad Genetics as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, attractive valuation levels and impressive record of earnings per share growth. We feel these strengths outweigh the fact that the company has had lackluster performance in the stock itself. Highlights from the ratings report include:
- MYGN's very impressive revenue growth greatly exceeded the industry average of 11.1%. Since the same quarter one year prior, revenues leaped by 51.7%. Growth in the company's revenue appears to have helped boost the earnings per share.
- MYGN has no debt to speak of therefore resulting in a debt-to-equity ratio of zero, which we consider to be a relatively favorable sign. Along with this, the company maintains a quick ratio of 5.63, which clearly demonstrates the ability to cover short-term cash needs.
- Current return on equity exceeded its ROE from the same quarter one year prior. This is a clear sign of strength within the company. When compared to other companies in the Biotechnology industry and the overall market, MYRIAD GENETICS INC's return on equity exceeds that of the industry average and significantly exceeds that of the S&P 500.
- MYRIAD GENETICS INC reported significant earnings per share improvement in the most recent quarter compared to the same quarter a year ago. The company has demonstrated a pattern of positive earnings per share growth over the past two years. We feel that this trend should continue. During the past fiscal year, MYRIAD GENETICS INC increased its bottom line by earning $1.77 versus $1.30 in the prior year. This year, the market expects an improvement in earnings ($1.98 versus $1.77).
- You can view the full Myriad Genetics Ratings Report.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.